跳至主要内容
临床试验/EUCTR2019-002474-30-IT
EUCTR2019-002474-30-IT进行中(未招募)1 期

PERSONALIZED MOLECULAR DRIVEN SURGERY ACCORDING TO BRCA MUTATIONAL STATUS IN ADVANCED EPITHELIAL OVARIAN CANCER PATIENTS WITH HIGH TUMOR LOAD - NIRAMUN/NOM

FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE0 个研究点目标入组 210 人开始时间: 2021年6月17日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
210

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • 1. Diagnosis of advanced epithelial ovarian cancer (FIGO stage III B-IV)
  • 2. high tumor load assessed by laparoscopy according to the Fagotti’s score (PIV 8-12)
  • 3. age between 18 and 80
  • 4. Performance Status (ECOG) = 2, an adequate respiratory, hepatic, cardiac, bone marrow, liver and renal function (Creatinine Clearance > 60 mL/min according to Cockroft formula)
  • 5. sBRCA-wt
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 150
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 60

排除标准

  • 1. FIGO stages IA-IIIA ii
  • 2. any histology but high grade serous
  • 3. hepatic dysfunction defined as a Model for End-Stage Liver Disease score of 10 or greater, renal dysfunction defined as serum creatinine of 2.0 mg/dL or greater
  • 4. history of any type of cancer in the past 5 years
  • 5. concomitant other malignancies
  • 6. pregnancy or lactation
  • 7. refusal to provide written informed consent.

研究者

发起方
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE

相似试验